High Quality Research-Non Cancer Disease

In more recent studies - we have seen positive research using the Kazia drug paxalisib in somewhat rare CNS disease.

But investors will love reading this information, from a top 10 medical research university in the UK......released on the web, a few hours ago.....  from the Centre for Biomedical Sciences, School of Biological Sciences, Royal Holloway University of London.

It is very deep research, which you will note.

Quote here from this London Royal Holloway University - which highlights just absolute stunning new information, as to the potential of paxalisib.

_______________________________________________________________________

• Article
• Open Access
• Published: 19 May 2023

Enhanced Sestrin expression through Tanshinone 2A treatment improves PI3K-dependent inhibition of glioma growth

• Judith Schaf,
• Sonia Shinhmar,
• Qingyu Zeng,
• Olivier E. Pardo,
• Philip Beesley,
• Nelofer Syed &
• Robin S. B. Williams

Cell Death Discovery volume 9, Article number: 172 (2023) Cite this article

• Metrics

Inactivation of mTORC1 through combinatory treatment with Paxalisib and T2A may provide a useful approach in treating other diseases arising from PI3K/PKB/mTORC1 dysregulation. These diseases include many cancer types such as blader [68], ovarian [69], breast [70, 71] and non-small cell lung cancers [72] as well as inflammatory diseases like restenosis and neointimal hyperplasia [73]. It may also provide novel approaches in the treatment of a variety of neurological diseases such as epilepsy [74,75,76], and autism spectrum disorder [77] and metabolic disorders including Type II Diabetes Mellitus [78]. Thus, using PI3K inhibitors and T2A in combination may be beneficial to the treatment of a range of diseases.

-------------------------------------------------------------------
It is fair to scrutinize, exactly who produced this highly detailed study. So more below on the Royal Holloway University, London.

From Wikipedia, the free encyclopedia

	Column 1	Column 2	Column 3	Column 4	Column 5	Column 6	Column 7	Column 8	Column 9	Column 10	Column 11	Column 12	Column 13	Column 14	Column 15	Column 16	Column 17
0	{caption}Royal Holloway, University of London{/caption}
1
2	Motto	Esse quam videri (Latin)
3	Motto in English
4	To be, rather than to seem (to be)
5	Type	Public research university
6	Established	1849: Bedford College1879: Royal Holloway College1900: became a constituent college of the University of London1985: merger of Bedford College and Royal Holloway College
7	Parent institution
8	University of London
9	Endowment	£86.1 million (2022)[1]
10	Budget	£201.1 million (2021–22)[1]
11	Chancellor	The Princess Royal(as Chancellor of the University of London)
12	Principal	Julie Sanders[2]
13	Academic staff
14	1,165 (2021/22)[3]
15	Administrative staff
16	1,055 (2021/22)[3]
17	Students	12,480 (2021/22)[4]
18	Undergraduates	9,685 (2021/22)[4]
19	Postgraduates	2,795 (2021/22)[4]
20	Location	Egham, Surrey, England
21	Campus	Suburban
22	Colours	Column 1 0

Affiliations| ACUAMBAEUAUniversities UK
Website| www.royalholloway.ac.uk
[/table]
Royal Holloway, University of London (RHUL), formally incorporated as Royal Holloway and Bedford New College, is a public research university and a constituent college of the federal University of London. It has six schools, 21 academic departments and approximately 10,500 undergraduate and postgraduate students from over 100 countries.^[5] The campus is located west of Egham, Surrey, 19 miles (31 km) from central London.

Royal Holloway maintains strong links and exchange programmes with institutions in the United States, Canada, Australia, and Hong Kong, notably the University of California & Yale University, the University of Toronto, the University of Melbourne and the University of Hong Kong.^[7]